Strategies to optimize siRNA delivery to hepatocellular carcinoma cells
Lucia Scarabel1, Francesca Perrone2, Marica Garziera1
1a Experimental and Clinical Pharmacology Unit , C.R.O. National Cancer Institute , Aviano , Italy.
Introduction:
hepatocellular carcinoma (hcc) is the predominant form of primary liver cancer and the second leading cause of cancer-associated mortality worldwide. available therapies for hcc have limited efficacy due to often late diagnosis and the general resistance of hcc to anti-cancer agents; therefore, the development of novel therapeutics is urgently required. small-interfering rna (sirna) molecules are short, double-stranded rnas that specifically recognize and bind the mrna of a target gene to inhibit gene expression. despite the great therapeutic potential of sirnas towards many human tumors including hcc, their use is limited by suboptimal delivery. Areas covered: In this review, we outline the current data regarding the therapeutic potential of siRNAs in HCC and describe the development of effective siRNA delivery systems. We detail the key problems associated with siRNA delivery and discuss the possible solutions. Finally, we provide examples of the various siRNA delivery strategies that have been employed in animal models of HCC and in human patients enrolled in clinical trials. Expert opinion: Despite the existing difficulties in siRNA delivery for HCC, the increasing scientific attention and breakthrough studies in this field is facilitating the design of novel and efficient technical solutions that may soon find practical applications.
Insights
Hepatocellular carcinoma (HCC) therapies are limited, necessitating new treatments. Small-interfering RNA (siRNA) shows promise for HCC, but effective delivery systems are crucial for its therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited treatment efficacy.
- Current HCC therapies face challenges due to late diagnosis and drug resistance.
- Novel therapeutic strategies are urgently needed for effective HCC treatment.
Purpose of the Study:
- To review the therapeutic potential of small-interfering RNA (siRNA) in HCC.
- To describe the development of effective siRNA delivery systems for HCC.
- To discuss challenges and solutions for siRNA delivery in HCC treatment.
Main Methods:
- Literature review of current data on siRNA therapeutics for HCC.
- Analysis of siRNA delivery systems, challenges, and potential solutions.
- Examination of siRNA delivery strategies in preclinical and clinical HCC studies.
Main Results:
- siRNA holds significant therapeutic potential for HCC.
- Suboptimal siRNA delivery remains a major limitation for its clinical application.
- Various delivery strategies are being explored in animal models and human trials.
Conclusions:
- Despite delivery challenges, ongoing research is advancing siRNA technology for HCC.
- Novel and efficient siRNA delivery solutions are emerging.
- These advancements may lead to practical applications in HCC therapy soon.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:15Experimental RNAi